VRDN:NASDAQViridian Therapeutics, Inc. Analysis
Data as of 2026-09-01 - not real-time
$23.16
Latest Price
9/10Risk
Risk Level: High
Executive Summary
At $23.16, Viridian Therapeutics, Inc. shows no decisive moving-average alignment, leaving the trend neutral. Over a rolling month the price has gained 24.8%. With RSI at 56.3 the momentum picture is neutral, alongside a bearish MACD signal. Price has been bracketed by support at $19.41 and resistance at $24.86.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 58.1% above where the shares trade now. Revenue is growing at 278.7%.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 46.0%, a beta of 1.08 and a maximum drawdown of 60.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 2/10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 58.1% above where the shares trade now. Revenue is growing at 278.7%.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 46.0%, a beta of 1.08 and a maximum drawdown of 60.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 2/10.
Top Market Events
Viridian Therapeutics Inc. NASDAQ:VRDN is one of the 10 affordable biotech stocks to buy right now. On June 30, Goldman...Morningstar%2c Inc.26dViridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026...Yahoo Finance1monLumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics VRDN The above button links...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Trading below the 200-day average of 23.90
- MACD momentum is negative
- 30-day price change of +24.8%
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Trading below the 200-day average of 23.90
- Analyst targets imply +58.1% versus the current price
- 30-day volatility of 46.0%
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- Analyst targets imply +58.1% versus the current price
- Negative return on equity of -65.7%
- Revenue growth of +278.7%
Key Metrics & Analysis
Financial Health
Revenue Growth278.70%
P/E Ratio-8.4
ROE-65.74%
ROA-30.16%
Debt/Equity36.96
P/B Ratio4.7
Op. Cash Flow$-333343008
Free Cash Flow$-275496000
Industry P/E30.4
Technical Analysis
TrendNeutral
RSI56.3
Support$19.41
Resistance$24.86
MA 20$23.21
MA 50$20.64
MA 200$23.90
MACDBearish
VolumeDecreasing
Fear & Greed Index93.34
Valuation
Target Price$36.63
Upside/Downside58.14%
GradeFair
TypeGrowth
Risk Assessment
Beta1.08
Volatility46.03%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.